Selexis actions to support the global response to COVID-19
Cell Line Development
Selexis SA, A JSR Life Sciences Company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines.
SUREtechnology Platform™
Our global partners are utilizing Selexis gene technologies to advance more than 130 drug products in clinical development and the manufacture of seven commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks.
LATEST NEWS
XPRESSIONS BLOG
RECENT AND UPCOMING EVENTS
In our webinar “Next-generation cell line development platform for advanced bispecific antibodies expression,” we will address the key challenges of expressing bispecifics in Chinese hamster ovary (CHO) cells.
Tuesday, June 23 | EU 1:00 PM CEST – US 9:00 AM PST
FEATURED CONTENT
Selexis Corporate Overview Q1 2019
Selexis SA is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines.
“The joint efforts of Russian, U.S. and Swiss scientists have made it possible to achieve significant progress in the development of high-tech medicines for the treatment of rare diseases such as a PNH and aHUS, with the economic benefits of local production. We believe working with Selexis improves the quality of our products and we are proud to take another step forward in helping the clinical community in Russia in their fight against rare diseases.”
“These two products are groundbreaking treatments that can extend accessibility to a much larger patient population. As a cell line development expert and well-established partner of Turgut’s, Selexis’ tools and technologies are giving us the competitive edge we need to forge ahead with our biosimilar programs. We look forward to achieving progress in these programs.”
The productivity and effectiveness of our initial work with Selexis made it an easy decision to apply the company’s protein expression platform to additional Teneobio preclinical candidates,” said Omid Vafa, PhD, MBA, chief business officer at Teneobio, Inc. “We look forward to continuing to work with Selexis as we bring our programs into the clinic.”
“We have successfully used the Selexis’ platform to drive our lead anti-CTLA4 (AGEN1884) and anti-PD1 (AGEN2034) programs, and are excited to partner with them to advance our novel single agent and multi-specific antibody programs.”
“Selexis is continually optimizing its proprietary cell line and technology platform to enable partners such as Amgen to make better R&D decisions by generating reliable data points faster and more cost efficiently.”
“Faron expects that the agreement with Selexis will serve to significantly improve the chances of success and to accelerate this value realization for Faron stakeholders.”
“The productivity and speed of stable cell line generation with the SUREtechnology Platform™ is playing a key role in quickly progressing our candidate into clinical development.”
“The productivity and speed of stable cell line generation with the SUREtechnology Platform™ is playing a key role in quickly progressing our candidate into clinical development.”
